Pediapharm Inc.
TSX VENTURE : PDP

Pediapharm Inc.

July 24, 2014 07:30 ET

Pediapharm Inc.: Naproxen Suspension Available in Canada Through a Special Access Program (SAP)

MONTREAL, QUEBEC--(Marketwired - July 24, 2014) -

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Pediapharm Inc. ("Pediapharm") (TSX VENTURE:PDP) announced today that further to its press release of July 2nd, 2014, a Special Access Program' (SAP) from Health Canada has been initiated for Naproxen suspension. This program allows physicians to prescribe the product to their patients when no commercially available alternatives are available. This program has been initiated at the request of physicians mainly treating patients suffering of Juvenile Rheumatoid Arthritis (JRA). The product will be made available through Pediapharm and the SAP will be in place until the availability of Pediapharm Naproxen Suspension.

On July 2, 2014, Pediapharm announced an asset purchase agreement regarding the Canadian rights to naproxen suspension from Hoffman-La Roche Limited ("Roche"). Roche will retain the Naprosyn™ trademark and retains all product rights to the other oral dosage forms under this brand.

Information regarding this program can be obtained by contacting the SAP office or by visiting http://drugshortages.ca

Information will also be disseminated by the Canadian Rheumatology Association to its member.

About Hoffmann-La Roche Limited

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

Naprosyn™ is a trademark of Hoffmann-La Roche Limited.

About Pediapharm Inc.

Pediapharm is the only Canadian specialty pharmaceutical company dedicated to serving the needs of the pediatric community. Its mission is to bring to the Canadian market the latest innovative pediatric products with the objective to improve the health and the well-being of children in Canada. Since its debut in 2008, Pediapharm has entered into numerous commercial agreements with partners from Canada and other countries around the world.

FORWARD LOOKING STATEMENTS FOR PEDIAPHARM

This news release contains forward-looking statements and other statements that are not historical. Such forward-looking statements are subject to known and unknown risks, uncertainties and assumptions that could cause actual results to vary materially from target results and the results or events predicted in these forward-looking statements. As a result, investors are cautioned not to place undue reliance on these forward-looking statements.

The forward-looking statements contained in this news release are made as of the date of this release. Except as required by applicable law, the Corporation disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking information reflects the current expectations or belief of the Corporation based on information currently available and such information is subject to a number of assumptions, risks and uncertainties described in details at pp. 35 to 41 of the Management Information Circular of Chelsea Acquisition Corporation dated November 12, 2013 available on SEDAR at www.sedar.com and other risks associated with being a specialty pharmaceutical company.

For more information about Pediapharm or its products, please visit www.pedia-pharm.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information